89886-73-7

Basic information

• Product Name: 2,3-Oxiranedicarboxylicacid,monoethylester,(2S,3S)-(9CI)
• Synonyms: 2,3-Oxiranedicarboxylicacid,monoethylester,(2S,3S)-(9CI);(2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid;(2S,3S)-2,3-Oxiranedicarboxylic Acid Monoethyl Ester;(2S,3S)-3-(Ethoxycarbonyl)oxirane-2-carboxylic acid 95%
• CAS NO: 89886-73-7
• Molecular Formula: C₆H₈O₅
• Molecular Weight: 160.13
• Product Categories: CARBOXYLICESTER;CARBOXYLICACID
• Mol File: 89886-73-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 278.9±40.0 oC (760 Torr)
• Flash Point: 118.5±20.8 oC
• Appearance: /
• Density: 1.447±0.06 g/cm3 (20 oC 760 Torr)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.14±0.40(Predicted)
• CAS DataBase Reference: 2,3-Oxiranedicarboxylicacid,monoethylester,(2S,3S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Oxiranedicarboxylicacid,monoethylester,(2S,3S)-(9CI)(89886-73-7)
• EPA Substance Registry System: 2,3-Oxiranedicarboxylicacid,monoethylester,(2S,3S)-(9CI)(89886-73-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• Hazardous Substances Data: 89886-73-7(Hazardous Substances Data)

Usage

Uses

(2S,3S)-2,3-Oxiranedicarboxylic Acid Monoethyl Ester is used in the synthesis of aza-peptidyl inhibitors of lysosomal asparaginyl endopeptidase, legumain. Also used in the synthesis of irreversible epidermal growth factor receptor inhibitors and probes for cathespins.

Upstream product

• 3291-46-1 (2S,3S)-diethyl oxirane-2,3-dicarboxylate 
• 3291-46-1 (2SR,3SR)-oxirane-2,3-dicarboxylic acid diethyl ester 
• 80640-15-9 diethyl (2S,3R)-(+)-erythro-2-hydroxy-3-bromosuccinate 
• 13811-71-7 diethyl (2S,3S)-tartrate 
• 57968-71-5 (+/-)-diethyl tartrate 

Downstream Products

• 500228-05-7 (+)-(2S,3S)-3-{{(1S)-1-{{4-{[(Benzyloxy)carbonyl]amino}butyl}{3-{[(benzyloxy)carbonyl]amino}propyl}carbamoyl}-2'-[4-(benzyloxy)phenyl]ethyl}carbamoyl}oxiran-2-carbonsaeure-ethylester 
• 1448429-23-9 (2S,3S)-ethyl-3-((S)-1-oxo-1-((1-(4-sulfamoylphenyl)-1H-1,2,3-triazol-4-yl)methylamino)-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-24-0 (2S,3S)-ethyl-3-((S)-1-((1-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-25-1 (2S,3S)-ethyl-3-((S)-1-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-26-2 (2S,3S)-ethyl-3-((S)-1-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-27-3 (2S,3S)-ethyl-3-((S)-1-((1-(2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-28-4 (2S,3S)-ethyl-3-((S)-1-((1-mesityl-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-19-3 (2S,3S)-ethyl-3-((S)-1-oxo-1-(1-phenyl-1H-1,2,3-triazol-4-yl)methylamino-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-20-6 (2S,3S)-ethyl-3-((S)-1-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-21-7 (2S,3S)-ethyl-3-((S)-1-oxo-1-((1-(4-(piperidin-1-ylsulfonyl)phenyl)-1H-1,2,3-triazol-4-yl)methylamino)-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-30-8 (2S,3S)-ethyl 3-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-31-9 (2S,3S)-ethyl 3-((S)-1-(2,6-difluorophenylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-33-1 (2S,3S)-ethyl 3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-35-3 (2S,3S)-ethyl 3-((S)-1-(4-(4-fluorophenylsulfonamido)butylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylate 

Relevant articles and documents

2,3-EPOXY SUCCINYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or

Cysteine protease inhibitors and uses thereof

The invention provides for novel cysteine protease inhibitors and compositions comprising novel cysteine protease derivatives. The invention further provides for methods for treatment of neurodegenerative diseases comprising administration novel cysteine

Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors

Hyperactivation of the calcium-dependent cysteine protease calpain 1 (Cal1) is implicated as a primary or secondary pathological event in a wide range of illnesses and in neurodegenerative states, including Alzheimer's disease (AD). E-64 is an epoxide-containing natural product identified as a potent nonselective, calpain inhibitor, with demonstrated efficacy in animal models of AD. By use of E-64 as a lead, three successive generations of calpain inhibitors were developed using computationally assisted design to increase selectivity for Cal1. First generation analogues were potent inhibitors, effecting covalent modification of recombinant Cal1 catalytic domain (Cal1cat), demonstrated using LC-MS/MS. Refinement yielded second generation inhibitors with improved selectivity. Further library expansion and ligand refinement gave three Cal1 inhibitors, one of which was designed as an activity-based protein profiling probe. These were determined to be irreversible and selective inhibitors by kinetics studies comparing full length Cal1 with the general cysteine protease papain.